Ardent, LHP to merge into second-largest private for-profit hospital chain

Nashville, Tennessee-based Ardent Health Services and LHP Hospital Group of Plano, Texas, have entered into a merger agreement, the companies announced Oct. 5.

The financial terms of the deal weren’t disclosed, but the companies’ joint statement said the merger would create a 19-hospital, six-state system with $3 billion in revenue, employing around 18,000  (including 475 employed physicians) and offering more than 3,200 patient beds.

“This is a transformative growth opportunity for Ardent that will provide significant benefits to each of the communities our companies serve,” Ardent President and CEO David T. Vandewater, said in a statement. “In addition to combining two organizations with similar operating philosophies and a strong focus on local partnerships and collaboration, this transaction dramatically enhances our scale, diversity and geographic reachcreating new synergies that better position us for future growth and investment in new and existing markets. We look forward to working closely with the outstanding employees, physicians, nurses and partners associated with LHP to advance our shared goals.”

The companies said the new system, once combined, would be the second largest privately-owned for-profit hospital chain in the U.S.

The press release said day-to-day operations at individual hospitals aren’t expected to change. For the LHP hospitals that are operated as joint ventures, such as Panama City, Florida’s Bay Medical Center, Ardent would assume LHP’s responsibilities in those partnerships.

Ardent expects the deal to close by early next year. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.